Your search for "Digestive Health" found 10 matches:
Effects of complementary feeding on infant growth and gut health

Your baby may be eligible if they are: - Breastfed and/or formula fed - Younger than five months of age - Full term (> 37-weeks’ gestation) - Have not yet been introduced to solid foods This is a seven month-long study, from 5 to 12 months of age, with visits occurring every month. ...

Protocol #20-2232

SIB: A Randomized Parallel Comparison of Semaglutide versus Placebo on Intestinal Barrier Function in Type 2 Diabetes Mellitus

Volunteers needed for a research study examining the effects of once weekly semaglutide on intestinal barrier function in type 2 diabetics who are being treated with metformin only. Main procedures involve blood draws, lactulose mannitol ratio (urine) test, stool samples, and once-weekly s...

Protocol #21-2774

Location: CTRC-adult

Copeptin and Nonalcoholic Fatty Liver Disease

See above...

Protocol #17-1160

Locations: Anschutz Health and Wellness, Outpatient CTRC, UCD Anschutz Health & Wellness Center, University of Colorado Hospital

A Longitudinal Observational Study of Patients with Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

Protocol #17-0051

Location: University of Colorado Hospital

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis

This study will be conducted in 2 sequential stages. You are being invited to participate in both stages of this study. The entire study period will be of approximately 39 months. Stage 1 (Phase 2b) will include approximately 315 patients and will consist of a screening period (about 2...

Protocol #20-2433

Location: Outpatient CTRC, University of Colorado Hospital

A Double-blind Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients with Primary Biliary Cholangitis with Inadequate Response or Intolerance to Ursodeoxycholic Acid

This is a phase 3 double-blind (DB), randomized, placebo-controlled study with an open-label long term extension (LTE) evaluating the efficacy and safety of Elafibranor 80 mg once daily versus placebo in patients with PBC and inadequate response or intolerance to ursodeoxycholic acid (UD...

Protocol #20-2899

Location: Outpatient CTRC, University of Colorado Hospital

Pediatric Polyposis Syndromes

Protocol #20-2981

Location: Childrens Hospital Colorado

A Phase 2b, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Efficacy and Safety of Saroglitazar Magnesium in Subjects with Nonalcoholic Steatohepatitis and Fibrosis

Protocol #21-3466

Location: University of Colorado Hospital

A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Evaluating the Safety and Efficacy of Semaglutide, and the Fixed-Dose Combination of Cilofexor and Firsocostat, Alone and in Combination, in Subjects with Compensated Cirrhosis (F4) due to Nonalcoholic Steatohepatitis (NASH)

Protocol #21-4639

Location: University of Colorado Hospital

Effect of Amino Acids on Hepatic Fat Content in Adolescents (AMINOS Study)

This study plans to investigate if taking a protein nutrition supplement (EAA) for 8 weeks may reduce fat that is stored in the liver. This will be compared to 8 weeks of placebo (a “fake” supplement that does not contain protein). Participants will be assigned randomly either the protein ...

Protocol #23-0690

Location: Brain Imaging Center (BIC), Brain Imaging Center - BIC, Childrens Hospital Colorado, Outpatient CTRC, University of Colorado Hospital